|
WO2021061867A1
|
|
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
WO2020252349A1
|
|
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
WO2020252358A1
|
|
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
|
|
WO2020236679A1
|
|
Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
|
|
WO2020176672A1
|
|
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
|
US2020377602A1
|
|
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
WO2020092881A1
|
|
Activatable anti-cd166 antibodies and methods of use thereof
|
|
EP3788077A1
|
|
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CN112005304A
|
|
Systems and methods for quantitative pharmacological modeling of activatable antibody species in a mammalian subject
|
|
WO2019173771A1
|
|
Activatable cd147 antibodies and methods of making and use thereof
|
|
WO2019165143A1
|
|
Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
|
|
KR20200064096A
|
|
Antibodies, activatable antibodies, bispecific antibodies and bispecific activatable antibodies and methods of using them
|
|
US2019117789A1
|
|
Activatable anti-cd166 antibodies and methods of use thereof
|
|
AU2018304711A1
|
|
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
|
SG11202000105QA
|
|
Anti-cd166 antibodies and uses thereof
|
|
CA3064588A1
|
|
Activatable anti-pdl1 antibodies, and methods of use thereof
|
|
CN110914302A
|
|
Activatable anti-PDL 1 antibodies and methods of use thereof
|
|
EP3592775A1
|
|
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
|
CN108368170A
|
|
Anti- PD-1 antibody can activate anti-PD-1 antibody and its application method
|
|
AU2016258628A1
|
|
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
|
